Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HAROLD EDWARD BAYS

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1316953920
CMS profile
105280
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$23,753.00

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $13,322.64 37
Consulting Fee $9,300.00 3
Food and Beverage $1,130.36 17

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $12,873.54 43
PFIZER INC. $4,150.00 1
Boehringer Ingelheim Pharmaceuticals, Inc. $2,650.00 1
Lilly USA, LLC $2,500.00 1
Merck Sharp & Dohme LLC $1,209.78 9
Novo Nordisk Inc $369.68 2

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HAROLD EDWARD BAYS

NPI 1316953920 · CMS profile ID 105280

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316953920?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HAROLD EDWARD BAYS, NPI 1316953920, CMS profile ID 105280. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316953920?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HAROLD EDWARD BAYS, NPI 1316953920, CMS profile ID 105280. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316953920?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HAROLD EDWARD BAYS, NPI 1316953920, CMS profile ID 105280, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316953920?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $23,753.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–57 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $294.2903/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031691679 CMS
Eli Lilly and Company $100.3003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031691685 CMS
Eli Lilly and Company $18.0803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031691691 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031691697 CMS
Eli Lilly and Company $34.9803/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031691701 CMS
PFIZER INC. $4,150.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050584613 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,650.0001/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996938000 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,654.11 41
PY2020 $16,717.50 8
PY2021 $52,060.79 32
PY2022 $19,733.88 31
PY2023 $23,753.00 57
PY2024 $54,022.54 71
PY2025 $38,254.18 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,392.11 1
PY2025 Principal investigator $2,776,415.66 388
PY2024 Recipient $17,558.24 14
PY2024 Principal investigator $2,751,773.83 181
PY2023 Recipient $3,459.92 16
PY2023 Principal investigator $1,622,368.04 405
PY2022 Recipient $8,520.43 11
PY2022 Principal investigator $1,178,031.70 911
PY2021 Recipient $1,667.60 2
PY2021 Principal investigator $1,731,114.04 1,163
PY2020 Recipient $7,743.85 3
PY2020 Principal investigator $1,462,762.40 727
PY2019 Recipient $1,577.23 1
PY2019 Principal investigator $1,134,037.01 573

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

389 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,968.00 12/31/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533641
Principal investigator 1 Eli Lilly and Company $26,836.00 12/30/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3B STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-8) No dispute reported 06/30/2026 1187884964
Principal investigator 1 ABBVIE INC. $427.50 12/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202531744
Principal investigator 1 Ionis Pharmaceuticals, Inc. $250.00 12/23/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS6 No dispute reported 06/30/2026 1246791756
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 12/23/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS6 No dispute reported 06/30/2026 1246791763
Principal investigator 1 Ionis Pharmaceuticals, Inc. $700.00 12/23/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS6 No dispute reported 06/30/2026 1246791767
Principal investigator 1 Ionis Pharmaceuticals, Inc. $109.50 12/22/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS6 No dispute reported 06/30/2026 1246791734
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,420.00 12/22/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246791739
Principal investigator 1 Ionis Pharmaceuticals, Inc. $430.00 12/22/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246791743
Principal investigator 1 Eli Lilly and Company $5,000.00 12/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
Not supplied No dispute reported 06/30/2026 1187886768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,856.25 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,617.50 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,055.00 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,844.62 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.28 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $562.08 12/11/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274715
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,325.70 12/10/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799698
Principal investigator 1 PFIZER INC. $351.00 12/10/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228732498
Principal investigator 1 ABBVIE INC. $4,420.00 12/05/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529292
Principal investigator 1 ABBVIE INC. $3,500.00 12/04/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202527252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $281.04 12/04/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269383
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691595
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691597
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691599
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691601
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691603
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 12/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691763
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,500.00 11/26/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799696
Principal investigator 1 PFIZER INC. $4,000.00 11/25/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228720481
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691605
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 11/19/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691607
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 11/19/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691609
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $281.04 11/14/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261503
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,689.00 11/13/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799694
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,982.30 11/07/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246790173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $382.20 11/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.77 11/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,250.00 11/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.56 11/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257757
Principal investigator 1 ABBVIE INC. $45,958.90 11/05/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522657
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691591
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691593
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691759
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 11/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691761
Principal investigator 1 PFIZER INC. $6,212.71 11/01/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228737709
Principal investigator 1 Novo Nordisk AS $366.75 10/29/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213724022
Principal investigator 1 ABBVIE INC. $1,580.00 10/27/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63.75 10/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,237.50 10/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,321.25 10/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $656.28 10/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,555.36 10/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252712
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $350.00 10/17/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799674
Principal investigator 1 Ionis Pharmaceuticals, Inc. $430.00 10/17/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246789390
Principal investigator 1 ABBVIE INC. $838.50 10/16/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,965.25 10/16/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250799
Principal investigator 1 Ionis Pharmaceuticals, Inc. $430.00 10/13/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246788792
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,971.50 10/10/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799668
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,500.00 10/10/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS9 No dispute reported 06/30/2026 1246788671
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,725.00 10/10/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS9 No dispute reported 06/30/2026 1246788675
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,200.00 10/10/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS9 No dispute reported 06/30/2026 1246788680
Principal investigator 1 Ionis Pharmaceuticals, Inc. $19,684.90 10/10/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS9 No dispute reported 06/30/2026 1246788685
Principal investigator 1 ABBVIE INC. $36,314.20 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,618.75 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,711.18 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63.75 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $712.56 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,037.88 10/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,254.81 10/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244785
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691583
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691585
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691587
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691589
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 10/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691755
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691757
Principal investigator 1 GlaxoSmithKline, LLC. $8,392.35 09/29/2025 Non-covered Recipient Entity
PHARMASEEK
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192142470
Principal investigator 1 ABBVIE INC. $110.00 09/25/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512302
Principal investigator 1 ABBVIE INC. $301.60 09/25/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512304
Principal investigator 1 ABBVIE INC. $213.06 09/25/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512322
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691581
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691753
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,010.00 09/23/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,665.00 09/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $998.00 09/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,295.00 09/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,327.57 09/23/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241730
Principal investigator 1 Novo Nordisk AS $1,471.50 09/19/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213718167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 09/18/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,858.31 09/18/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240622
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,318.85 09/10/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,278.17 09/10/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235877
Principal investigator 1 PFIZER INC. $7,565.04 09/06/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228758857
Principal investigator 1 ABBVIE INC. $25,675.00 09/04/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 09/04/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235261
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,615.40 09/03/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799670
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,275.90 09/03/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,851.86 09/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235019
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691559
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691561
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691563
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691565
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691717
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691719
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691721
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691723
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691725
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,509.62 08/26/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230447
Principal investigator 1 PFIZER INC. $4,897.76 08/23/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228786614
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 08/21/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799664
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,651.40 08/20/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,325.43 08/14/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228375
Principal investigator 1 Ionis Pharmaceuticals, Inc. $12,228.30 08/08/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246786412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,858.31 08/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226245
Principal investigator 1 ABBVIE INC. $31,302.70 08/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502897
Principal investigator 1 PFIZER INC. $20,462.70 08/02/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228785734
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691551
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691553
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691555
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691557
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 08/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691739
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691743
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,075.20 08/01/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799662
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 08/01/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/31/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $417.56 07/31/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222926
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691575
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691577
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 07/28/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691579
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 07/28/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691747
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 07/28/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691749
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 07/28/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691751
Principal investigator 1 ABBVIE INC. $5,000.00 07/24/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202499654
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,485.00 07/24/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS6 No dispute reported 06/30/2026 1246785570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,389.90 07/22/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.28 07/22/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $417.56 07/22/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217875
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 07/21/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799660
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $425.00 07/20/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799658
Principal investigator 1 Novo Nordisk AS $840.72 07/18/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213799628
Principal investigator 1 Novo Nordisk AS $1,104.75 07/18/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213810062
Principal investigator 1 PFIZER INC. $337.35 07/17/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,088.54 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,430.48 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $919.17 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $740.28 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,672.37 07/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217214
Principal investigator 1 PFIZER INC. $21,310.56 07/12/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228719813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,672.37 07/10/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214460
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,036.70 07/09/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799686
Principal investigator 1 Eli Lilly and Company $340,498.71 07/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187884512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,212.31 07/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212637
Principal investigator 1 ABBVIE INC. $28,327.00 07/02/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494499
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691567
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691569
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691571
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691573
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691727
Principal investigator 1 Boehringer Ingelheim International GmbH $61.58 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691729
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691731
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691733
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691735
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691737
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691741
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,256.70 07/01/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799656
Principal investigator 1 Ionis Pharmaceuticals, Inc. $200.00 06/27/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246784809
Principal investigator 1 Ionis Pharmaceuticals, Inc. $430.00 06/27/2025 Non-covered Recipient Entity
L-MARC RESEARCH CENTER
IS354CS15 No dispute reported 06/30/2026 1246784813
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,004.50 06/25/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799684
Principal investigator 1 Novo Nordisk AS $366.75 06/25/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213835321
Principal investigator 1 PFIZER INC. $26,420.29 06/25/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228774506
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691543
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691545
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691547
Principal investigator 1 Boehringer Ingelheim International GmbH $24.84 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691549
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691707
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691709
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691711
Principal investigator 1 Boehringer Ingelheim International GmbH $41.40 06/24/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,212.31 06/24/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $851.22 06/19/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,629.87 06/19/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209265
Principal investigator 1 ABBVIE INC. $1,440.00 06/18/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202492069
Principal investigator 1 ABBVIE INC. $1,365.00 06/18/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202492307
Principal investigator 1 Amgen Inc. $6,564.93 06/15/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246643681
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,049.20 06/12/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63.75 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,650.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,618.75 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,856.25 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,177.50 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,420.56 06/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $417.56 06/05/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204271
Principal investigator 1 ABBVIE INC. $54,835.30 06/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487547
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691535
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691537
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691539
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691541
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691697
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691699
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691701
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691703
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691705
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 06/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691715
Principal investigator 1 PFIZER INC. $13,472.91 05/30/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228772925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,629.87 05/22/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197675
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,200.00 05/21/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,212.31 05/15/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194811
Principal investigator 1 PFIZER INC. $29,177.28 05/13/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228771823
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 05/12/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220802326
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 05/12/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220802328
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $913.50 05/09/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,746.56 05/08/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193783
Principal investigator 1 ABBVIE INC. $37,252.80 05/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482953
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $68.71 05/06/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220802324
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,604.20 05/05/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799650
Principal investigator 1 PFIZER INC. $11,651.61 05/03/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228723174
Principal investigator 1 PFIZER INC. $24,602.23 05/02/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,371.31 05/02/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184191935
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691527
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691529
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691531
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691533
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691687
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691689
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691691
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691693
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 05/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $835.12 04/22/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184185273
Principal investigator 1 Novo Nordisk AS $18.50 04/21/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213727936
Principal investigator 1 Novo Nordisk AS $2,209.50 04/21/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213780450
Principal investigator 1 Novo Nordisk AS $982.49 04/21/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
NN9535-4352 No dispute reported 06/30/2026 1213818680
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $684.95 04/18/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799644
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $734.95 04/18/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799646
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,385.00 04/18/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799648
Principal investigator 1 PFIZER INC. $30,747.20 04/17/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228724032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,015.56 04/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184184766
Principal investigator 1 ABBVIE INC. $182.00 04/15/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202476457
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,355.20 04/11/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799642
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,294.70 04/10/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,365.31 04/10/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182914
Principal investigator 1 ABBVIE INC. $9,362.60 04/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202469940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,237.50 04/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $791.78 04/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.56 04/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181644
Principal investigator 1 Eli Lilly and Company $315.77 04/02/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187884962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691519
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691521
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691523
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691525
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691667
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691669
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691671
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691673
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691675
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691677
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691679
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 04/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691683
Principal investigator 1 Novo Nordisk AS $26,007.94 03/31/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
EX9924-4473 No dispute reported 06/30/2026 1213753699
Recipient Amgen Inc. $6,392.11 03/25/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246636936
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691515
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691517
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691659
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,003.00 03/25/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178816
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,398.80 03/24/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799678
Principal investigator 1 PFIZER INC. $27,128.55 03/21/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228781809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,465.69 03/20/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184175014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,222.69 03/14/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,759.12 03/14/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173962
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,661.60 03/13/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799640
Principal investigator 1 Eli Lilly and Company $1,916.14 03/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187886400
Principal investigator 1 ABBVIE INC. $15,840.50 03/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,618.75 03/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 03/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,031.12 03/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157155
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691499
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691501
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691503
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691505
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691633
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691635
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691637
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691639
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691641
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691643
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691645
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691507
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691509
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691511
Principal investigator 1 Boehringer Ingelheim International GmbH $24.84 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691513
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691653
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691655
Principal investigator 1 Boehringer Ingelheim International GmbH $41.40 02/25/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691657
Principal investigator 1 Eli Lilly and Company $449.75 02/25/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187884960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,050.63 02/25/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155472
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,672.20 02/20/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/20/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154970
Principal investigator 1 Eli Lilly and Company $25,553.00 02/14/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1187885740
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,385.00 02/13/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799636
Principal investigator 1 PFIZER INC. $8,530.62 02/13/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerosis Research Center
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228723582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,462.69 02/13/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153930
Principal investigator 1 Novartis Pharmaceuticals Corporation $170,423.20 02/10/2025 Non-covered Recipient Entity
L MARC
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190306059
Principal investigator 1 ABBVIE INC. $22,503.00 02/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,478.25 02/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152632
Principal investigator 1 Shionogi Inc $13,123.60 02/05/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250720450
Principal investigator 1 Eli Lilly and Company $23,978.00 02/04/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187885742
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691491
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691493
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691495
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691497
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691621
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691623
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691625
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691627
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691629
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,209.70 02/01/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799634
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,837.60 01/31/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi No dispute reported 06/30/2026 1185542926
Principal investigator 1 Eli Lilly and Company $1,220.60 01/31/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187884598
Principal investigator 1 Eli Lilly and Company $1,344.80 01/31/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187885448
Principal investigator 1 Eli Lilly and Company $5,351.67 01/31/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885744
Principal investigator 1 Novo Nordisk AS $2,000.00 01/31/2025 Non-covered Recipient Entity
L MARC RESEARCH CENTER
EX9924-4473 No dispute reported 06/30/2026 1213703298
Principal investigator 1 Eli Lilly and Company $1,861.27 01/30/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187886362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,628.07 01/29/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149936
Principal investigator 1 Eli Lilly and Company $36,603.00 01/28/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187884508
Principal investigator 1 GlaxoSmithKline, LLC. $2,930.51 01/28/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192142478
Principal investigator 1 Amgen Inc. $84,430.22 01/27/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1246643673
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 01/27/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691647
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 01/27/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691649
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 01/27/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,258.00 01/27/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220799676
Principal investigator 1 Eli Lilly and Company $85.53 01/24/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187886360
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,308.00 01/21/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799632
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13.75 01/21/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220802322
Principal investigator 1 Eli Lilly and Company $45,938.00 01/21/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187885446
Principal investigator 1 Eli Lilly and Company $19,727.00 01/21/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187885738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,101.26 01/17/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148195
Principal investigator 1 ABBVIE INC. $182.00 01/16/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202439095
Principal investigator 1 Eli Lilly and Company $233,664.00 01/13/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187886664
Principal investigator 1 Amgen Inc. $179,069.24 01/12/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246643677
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $684.95 01/09/2025 Non-covered Recipient Entity
Louisville Metabolic and Atherosclerotic Research Center Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220799630
Principal investigator 1 Madrigal Pharmaceuticals $2,308.80 01/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,651.45 01/09/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184147353
Principal investigator 1 Eli Lilly and Company $101,219.00 01/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187884602
Principal investigator 1 Eli Lilly and Company $85,553.53 01/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187886944
Principal investigator 1 Eli Lilly and Company $17,527.00 01/07/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187886946
Principal investigator 1 Eli Lilly and Company $269,418.15 01/06/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187884600
Principal investigator 1 GlaxoSmithKline, LLC. $44.55 01/06/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192142483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,618.75 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,867.50 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.00 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,079.00 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $581.00 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.80 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $213.75 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $191.25 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $176.05 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,719.13 01/03/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184144826
Principal investigator 1 Eli Lilly and Company $31.84 01/02/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187884510
Principal investigator 1 Eli Lilly and Company $2,518.50 01/02/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187886666
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691483
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691485
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691487
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220691489
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691613
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691615
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691617
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691619
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691663
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691665
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 01/01/2025 Non-covered Recipient Entity
L-Marc Research Center
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220691681